Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CCXI

ChemoCentryx (CCXI) Stock Price, News & Analysis

ChemoCentryx logo

About ChemoCentryx Stock (NASDAQ:CCXI)

Key Stats

Today's Range
$51.99
$51.99
50-Day Range
$51.66
$51.99
52-Week Range
$14.95
$52.00
Volume
113 shs
Average Volume
1.68 million shs
Market Capitalization
$3.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

ChemoCentryx Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
15th Percentile Overall Score

CCXI MarketRank™: 

ChemoCentryx scored higher than 15% of companies evaluated by MarketBeat, and ranked 897th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for ChemoCentryx.

  • Earnings Growth

    Earnings for ChemoCentryx are expected to grow in the coming year, from ($1.81) to ($0.75) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ChemoCentryx is -27.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ChemoCentryx is -27.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ChemoCentryx has a P/B Ratio of 12.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CCXI.
  • Dividend Yield

    ChemoCentryx does not currently pay a dividend.

  • Dividend Growth

    ChemoCentryx does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CCXI.
  • MarketBeat Follows

    1 people have added ChemoCentryx to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ChemoCentryx insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.30% of the stock of ChemoCentryx is held by insiders.

  • Percentage Held by Institutions

    81.09% of the stock of ChemoCentryx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ChemoCentryx's insider trading history.
Receive CCXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChemoCentryx and its competitors with MarketBeat's FREE daily newsletter.

CCXI Stock News Headlines

Rishi Gupta's Net Worth
Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
See More Headlines

CCXI Stock Analysis - Frequently Asked Questions

ChemoCentryx, Inc. (NASDAQ:CCXI) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.13. The biopharmaceutical company earned $17.74 million during the quarter, compared to the consensus estimate of $14.70 million. ChemoCentryx had a negative trailing twelve-month return on equity of 48.52% and a negative net margin of 357.01%.

Based on aggregate information from My MarketBeat watchlists, some other companies that ChemoCentryx investors own include Energy Transfer (ET), Gilead Sciences (GILD), Block (SQ), Exelixis (EXEL), Meta Platforms (META), HubSpot (HUBS) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/08/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CCXI
CUSIP
16383L10
Employees
178
Year Founded
N/A

Profitability

Net Income
$-131,760,000.00
Net Margins
-357.01%
Pretax Margin
-357.01%

Debt

Sales & Book Value

Annual Sales
$32.22 million
Book Value
$4.09 per share

Miscellaneous

Free Float
65,433,000
Market Cap
$3.71 billion
Optionable
Optionable
Beta
1.22

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CCXI) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners